Carl Zeiss Meditec AG

07/16/2021 | Press release | Distributed by Public on 07/16/2021 05:18

Publication of insider information pursuant to Art. 17 MAR

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 1,198.2 million after nine months of fiscal year 2020/21 (past year: EUR 967.9 million). This corresponds to a revenue development of +23.8% vs. the past year (after adjustment for currency effects1: +27.6%). In the third quarter of FY 2020/21, revenue amounted to EUR 430.8 million (past year: EUR 253.0 million) - a growth rate of +70.3% (after adjustment for currency effects: +75.3%) against the previous year's period which had been heavily impacted by the COVID-19 pandemic. Revenue benefitted from a rise in recurring revenues as well as a further recovery in demand for equipment.

Earnings before interest and taxes (EBIT)2 amounted to EUR 282.8 million after nine months of FY 2020/21 (past year: EUR 111.9 million). EBIT margin (EBIT / revenue) was 23.6% (past year 11.6%). In the third quarter of FY 2020/21, EBIT amounted to EUR 120.1 million (past year: EUR 9.4 million). EBIT margin was 27.9% (past year: 3.7%). EBIT benefitted from a favorable development of product mix with a high share of recurring revenue. In addition, the ongoing low level of sales and marketing expenses as a result of the COVID-19 pandemic contributed to EBIT compared to the past year.

Earnings per share (EPS)3 amounted to EUR 2.04 (past year: EUR 0.77) for nine months of FY 2020/21. In the third quarter, EPS amounted to EUR 0.91 (past year: EUR 0.06).

Full results for nine months 2020/21 will be published on August 6, 2021.

In light of the positive business development, the company is raising targets for the current fiscal year 2020/21: revenue is expected to exceed the previous forecast of approximately EUR 1.6 billion (past year: EUR 1,335.5 million). EBIT margin for fiscal year 2020/21 is projected to significantly exceed the previous forecast of approximately 20% (past year: 13.3%), with strong support from lower than usual sales and marketing expenses in the current year.